Actelion is granted marketing authorization for Uptravi (selexipag) in pulmonary arterial hypertension by the European Commission (Actelion Ltd)

(Source: Actelion Ltd) Marketing authorization granted by European Commission on 12 May 2016 First European Union (EU) market introduction to commence in the near future ALLSCHWIL, SWITZERLAND - 17 May 2016 - Actelion (SIX: ATLN) announced today that the European Commission has granted marketing authorization in the EU for the orally active, selective IP prostacyclin receptor agonist Uptravi (selexipag) for the treatment of pulmonary arterial hypertension. Uptravi is indicated for the long-term treatment of pulmonary arterial hypertension (PAH) in adult patients with WHO functional class (FC) II-III, either as combination therapy in patients insufficiently controlled with an endothelin...